Investigating how opioid use affects sleep and circadian rhythms
Official title: Medications for Opioid Use Disorder Differentially Modulate Intrinsically Photosensitive Retinal Ganglion Cell Function, Sleep, and Circadian Rhythms: Implications for Treatment (MOUD)
Run by University of Alabama at Birmingham · NCT06104280 · Data updated 2026-11-12
This study is trying to see how opioid use affects sleep and body clock patterns in people with opioid use disorder to find better ways to help them recover.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | University of Alabama at Birmingham Academic / other |
| Locations | 1 site (Birmingham, Alabama) |
| Status | Recruiting |
| Started | January 6, 2025 |
| Main results expected | December 28, 2028 |
| Study ends | January 1, 2029 |
| Registry record updated | August 11, 2026 |
| Trial ID | NCT06104280 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older who are stable on one of the three FDA-approved medications for opioid use disorder.
✕Probably not a fit
Patients with significant eye diseases or those who are acutely unstable or have severe substance use disorders may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to explore the relationship between opioid use disorder (OUD) and sleep disturbances, focusing on the role of photosensitive retinal ganglion cells in regulating circadian rhythms. It will involve 200 participants, including 150 individuals undergoing medication-assisted treatment for OUD with methadone, buprenorphine, or extended-release naltrexone. The study will utilize various assessments, such as polysomnography and ecological momentary assessments, to evaluate sleep patterns and potential biomarkers that could predict recovery and relapse. By understanding these mechanisms, the research seeks to identify novel interventions to improve treatment outcomes for patients with OUD.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies for individuals with opioid use disorder by addressing sleep disturbances.
How similar studies have gone: While the specific approach of examining retinal ganglion cell function in relation to opioid use and sleep is novel, related studies have shown the importance of sleep in recovery from substance use disorders.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Adults (18+) 2. prescribed one of three medications for opioid use disorder (methadone, XR-NTX, buprenorphine) or healthy control 3. stable on MOUD (no dose change) for the past month 4. positive on urine drug screen (UDS) for buprenorphine or methadone if prescribed those medications Exclusion Criteria: 1. eye disease reported by history or noted on exam including disease of the anterior and posterior segment of the eye, cataracts, retinopathy, glaucoma, cataracts, amblyopia, scotoma, color or night blindness, corneal pathologies, macular degeneration, or retinitis pigmentosa; 2. acutely suicidal, manic, intoxicated, or otherwise not stable enough to provide informed consent 3. self-reported use of illicit opioids, stimulants (prescribed or illicit), or benzodiazepines/sedative/hypnotics in the past month 4. alcohol or cannabis use disorder measured as severe on The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) Checklist 5. positive on UDS for illicit opioids (e.g., morphine, oxycodone, fentanyl),stimulants, benzodiazepines/sedative/hypnotics 6. shift workers who work outside normal 7 a.m. to 6 p.m. hours, according to the National Institute of Occupational Safety and Health (NIOSH) 7. persons diagnosed with narcolepsy
Where it's running
-
University of Alabama at Birmingham
Birmingham, Alabama, United States Recruiting
Study contacts
- Principal investigator: Karen Cropsey, PsyD — University of Alabama at Birmingham
- Study coordinator: Karen Gamble, PhD
- Email: kcropsey@uabmc.edu
- Phone: 205-975-7809
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Improving Sleep for Older Adults in the Emergency Department
This project tests whether wearing a Fitbit overnight can help understand and improve sleep for adults 70 and older in the emergency department who are likely to be admitted.
-
CBD for Opioid Dependence and Pain on Buprenorphine
This study tests whether different doses of cannabidiol (CBD) can affect pain and opioid cravings in adults with opioid use disorder who are on buprenorphine, using a short, randomized, placebo-controlled setup.
-
Cebranopadol for opioid withdrawal in adults with chronic pain
This study tests whether cebranopadol can reduce withdrawal symptoms in adults with chronic pain who are physically dependent on prescribed opioids, compared with placebo.
-
Virtual Reality-Based Hypnotherapy to Help Pain, Sleep, and Mood in Spinal Cord Injury
Adults with spinal cord injury will try adding short VR-based hypnotherapy sessions to their standard physiotherapy to see if it reduces pain and improves sleep and mood.
-
Telephone-Coached Sleep Bibliotherapy for Dementia Caregivers
This study tests whether an 8-week, telephone-guided sleep self-help program helps informal caregivers of people with dementia sleep better.
-
Sleep detection in long-term care residents
This study tests how well contactless sleep sensors track sleep patterns in older adults living in long-term care facilities.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.